From: Measurable residual disease in multiple myeloma: ready for clinical practice?
NCT | Study official title | Country | Technique |
---|---|---|---|
NCT02406144 | Maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and ixazomib after autologous hematopoietic stem cell transplantation in patients With newly diagnosed symptomatic multiple myeloma-duration of maintenance guided by MRD status (GEM2014MAIN) | Spain | NGF |
RADAR* | Risk adapted therapy directed according to response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma suitable for stem cell transplantation | UK | N/A |
NCT03490344 | Short course daratumumab in minimal residual disease (MRD) positive myeloma patients after induction therapy with/without consolidative high-dose chemotherapy/autologous stem cell support | USA | FC |
NCT03224507 | Monoclonal antibody-based sequential therapy for deep remission in multiple myeloma (MASTER) | USA | NGS |
NCT03742297* | Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide, and dexamethasone (KRd) plus/minus daratumumab, 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma patients aged between 65 and 80 years | Spain | NGF |
NCT03697655 | Pre-emptive daratumumab therapy of minimal residual disease reappearance or biochemical relapse in multiple myeloma (PREDATOR) | Poland | N/A |
NCT03710603 | A phase 3 study comparing daratumumab, VELCADE (Bortezomib), lenalidomide, and dexamethasone (D-VRd) vs VELCADE, lenalidomide, and dexamethasone (VRd) in subjects with previously untreated multiple myeloma who are eligible for high-dose therapy (PERSEUS) | EMN | N/A |
NCT03992170 | A pilot study on the efficacy of daratumumab in multiple myeloma (MM) patients in >VGPR/MRD-positive by next-generation flow (DART4MM) | Italy | FC |
NCT02969837 | Open-label, single-arm, phase 2 study of initial treatment with elotuzumab, carfilzomib (Kyprolis), lenalidomide (Revlimid), and low-dose dexamethasone (E-KRd) in newly diagnosed, multiple myeloma requiring systemic chemotherapy | USA | NGS and MFC |
NCT04071457 | S1803, phase III study of daratumumab/rHuPH20 (NSC-810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (DRAMMATIC study) | USA | NGS |
NCT04096066 | Carfilzomib-lenalidomide-dexamethasone (KRd) versus lenalidomide-dexamethasone (Rd) in newly diagnosed myeloma patients not eligible for autologous stem cell transplantation: a randomized phase III trial | Italy | N/A |
NCT03376477 | A randomized, double-blind, placebo-controlled phase II trial of an allogeneic myeloma GM-CSF vaccine with lenalidomide in multiple myeloma patients in complete or near complete | USA | NGS |
NCT04108624 | A multimodality approach to minimal residual disease detection to guide post-transplant maintenance therapy in multiple myeloma (MRD2STOP) | USA | NGS |
NCT04221178 | A single-arm, prospective atudy of maintenance therapy cessation for patients with multiple myeloma in sustained MRD-negative remissions | USA | NGF |
NCT04140162 | Phase 2 study with minimal residual disease (MRD) driven adaptive strategy in treatment for newly diagnosed multiple myeloma (MM) with upfront daratumumab-based therapy | USA | N/A |